Officer Robert Lechleider Files Intent to Sell $1.19M in Immunome Stock
IMNM has more than doubled off its 52-week low of $7.96 on light trading volume (0.3× avg).
Summary
Immunome Inc. officer Robert Lechleider filed a Form 144 to sell $1.19 million in stock, acquired via option exercise, continuing a recent trend of insider sales.
Key Events · Ownership and Investor Activity · IMNM
-
Officer Intent to Sell
Robert Lechleider, an officer, filed a Form 144 to sell 55,000 shares of common stock, valued at approximately $1.19 million.
-
Option Exercise and Sale
The shares intended for sale were acquired through a stock option exercise on the same day as the proposed sale, indicating a monetization event.
-
Continuing Insider Distribution
This filing adds to a pattern of insider selling, including a prior sale by the same officer on June 25, 2026, and aligns with a net distribution signal from insider activity over the past 90 days.
Analysis · IMNM · Life Sciences
An officer of Immunome Inc. has filed a Form 144 indicating intent to sell approximately $1.19 million worth of common stock. This follows a previous sale by the same officer on June 25, 2026, and contributes to a broader pattern of insider distribution observed over the last 90 days. The shares are being acquired through a stock option exercise on the same day as the proposed sale, suggesting a monetization event rather than a direct vote of no confidence, but still represents a reduction in direct holdings.
At the time of this filing, IMNM was trading at $22.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $7.96 to $27.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.